## NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Parkway, Suite 206 - Reno, NV 89521 - (775) 850-1440

## **Sterile Compounding Questionnaire**

Rev (08/02/2022)

## This application cannot be returned by fax or email. We must have an original signature to process.

Approval of this completed questionnaire is required for an existing pharmacy, new pharmacy and/or out-sourcing facility applicant who wish to engage in preparing, compounding, dispensing, and furnishing sterile compounded products to Nevada patients or consumers.

Please provide a thorough response to the questions below and provide any necessary supporting documents. -For a new pharmacy or out-sourcing facility applicant, submit this completed form with your application. -For an existing pharmacy, send the completed form to the address indicated above.

## **Section 1: General Information**

Pharmacy Name:			
NV Pharmacy or Outsourcing facility license # (if appl			
Physical Address:			
City:	State:	Zip:	
Mailing Address (if different from physical address):			
City:	State:	Zip:	
Telephone:	Toll Free # (NAC 639.708, NRS 639.232	36):	
Fax:	Contact Email:		
Website:			
Nevada Business License # (if applicable)			
Supervising/Managing Pharmacist Name (NRS 639.22	20):		
Supervising/Managing Pharmacist NV Pharmacist Reg	gistration #:		
Name of Person with direct knowledge of compound	ing procedures:		
Email of Person with direct knowledge of compoundi	ing procedures:		
Telephone of Person with direct knowledge of compo	ounding procedures:		

Section 2: Sterile Compounding Questions (Use a separate piece of paper if additional space	is needed.)		
1. What risk level sterile compounding will your facility be performing (check all that apply)? If you marked "High", you must also complete section 4.	□ Low	🗆 Medium	🗆 High
<ol> <li>Will you be performing sterile hazardous drug compounding?</li> <li>If you marked "Yes", you must also complete section 3.</li> </ol>		□ Yes	□ No
3. List the sterile compounded products that you will be compounding for Nevada patients or	consumers	:	
4. Will you be utilizing beyond use dates in excess of USP-797?		□ Yes	🗆 No
5. If yes, describe the additional testing performed on your products to validate the extended	BUD:		
6. What laboratory performs this additional testing?			
Name:			
Address:			
		Zip:	
Telephone:			
7. What is your procedure for visual inspection of compounded sterile products?			

8. H	How often	do you	perform	glove	fingertip	and	medial	fill	testing?
------	-----------	--------	---------	-------	-----------	-----	--------	------	----------

9. What is your policy if an employee fails a glove fingertip or media-fill test?

10. Describe your initial and annual training program for all personnel performing sterile compounding:

11. Describe the cleaning procedure for your primary and secondary engineering controls, including the frequency of cleaning and the names of cleaning, disinfectant, sporicidal, and/or deactivation and decontamination agents used:

12. Who performs the sterile compounding process at your facility?

13. Who is responsible and accountable for the sterile compounding process at your facility?

14. If products are shipped/mailed, what shipping conditions are used to ensure product safety/efficacy?

Section 3: Sterile Hazardous Compounding Questions (Complete this section ONLY if you be performing Sterile Hazardous	
Compounding.)	

1. What type of primary engineering controls will you be using in your facility?

2. Is your BSC or CACI vented 100% to the outside?	🗆 Yes	🗆 No
3. Do you have a negative pressure buffer room at your facility?	🗆 Yes	🗆 No
4. Will you be compounding with antineoplastic HDs or HD API?	🗆 Yes	🗆 No
5. If yes, are the drugs stored in an externally ventilated, negative pressure room?	🗆 Yes	🗆 No
6. Will you be utilizing a closed system transfer device?	🗆 Yes	🗆 No
7. If yes, list the name of the device:		

8. What information is provided to the patient or consumer on the proper handling and disposal of hazardous drugs products/containers?

9. Describe your initial process for training new employees prior to compounding sterile hazardous drugs?

Section 4: Sterile Hi Compounding.)	gh Risk Compounding C	Questions (Complete this sec	tion ONLY if you will be perfor	ming High Risk	
	gh risk sterile products	that your facility compounds	:		
2. What sterilization	methods are utilized at	t your facility?			
3. Does vour facility	utilize biological indicat	tors?		□ Yes	🗆 No
4. If yes, describe ho					
I certify under pe	nalty of perjury that the in	formation contained in this forr	n is accurate, true and complete in	all material resp	ects. I
understand that r	making any false represent	tation in this form is a crime unc	ler NRS 639.281. I understand that otherwise declared confidential by	, pursuant to NRS	
considered by the	e Nevada State Board of Ph	harmacy at a public meeting pur	suant to NRS 241.020. In the even	t the form is appr	
	with all applicable federal a result in discipline.	and state statutes and regulatio	ns governing this license or registra	tion and underst	and that
Name of Perso	n who Completed the Fo	orm			
 Title					
Signature (coni	es or stamps not accept	 ted)	 Date		
		,			
Board Use Only	Date Received:	Date Approved:	Approved By:		
<u> </u>					